SecBot SecBot
SECBOTREPLAY Home › Report › NAMS

NAMS · NewAmsterdam Pharma announced that the EMA's CHMP has adopted a…

NewAmsterdam Pharma Co N.V. · 8-K filed Jul 24, 2026 at 08:03 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jul 24, 2026 at 08:03 ET

NewAmsterdam Pharma announced that the EMA's CHMP has adopted a positive opinion recommending marketing authorization for Ubeslo (obicetrapib monotherapy) and Evlarco (obicetrapib plus ezetimibe fixed-dose combination) in Europe. The European Commission is expected to issue a final decision in 2H26, and if approved, this would enable commercialization of obicetrapib across EU member states, Iceland, Liechtenstein, and Norway, unlocking milestone payments of up to €833 million for NewAmsterdam plus tiered double-digit royalties on net sales in the Menarini territory.

  • CHMP adopted a positive opinion recommending marketing authorization for Ubeslo (obicetrapib 10 mg monotherapy) and Evlarco (10 mg obicetrapib plus 10 mg ezetimibe fixed-dose combination).
  • Recommendation is supported by Phase 3 BROADWAY, BROOKLYN, and TANDEM data showing up to ~40% LDL-C reduction with obicetrapib monotherapy and ~50% with the combination vs placebo.
  • European Commission decision expected in 2H26; if granted, authorization applies across all EU member states plus Iceland, Liechtenstein, and Norway.
  • NewAmsterdam is entitled to up to €833 million in clinical, regulatory, and commercial milestones plus tiered double-digit royalties (low double-digits to mid-twenties) on net sales in the Menarini territory.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access